menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Orion Makes Disclosure Under Chapter 9 Section 10 Securities

    GLOBENEWSWIRE

    Orion Corp: Disclosure Under Chapter 9 Section 10 Securities Mark

    GLOBENEWSWIRE

    Orion Corp: Disclosure Under Chapter 9 Section 10 Securities Mark

    GLOBENEWSWIRE

    Orion To Open Biologics R&D Centre In Cambridge In 2025

    GLOBENEWSWIRE

    Orion Corp: Disclosure Under Chapter 9 Section 10 Securities Mark

    GLOBENEWSWIRE

    Orion Corporation: Transfer of 191,911 B shares on 10 March 2025

    GLOBENEWSWIRE

    Orion and Aiforia extend collaboration to preclinical study evaluations

    PRESS RELASE

    Orion Disclosure Under Securities Market Act (BlackRock, Inc.)

    GLOBENEWSWIRE

    Orion Corp: Disclosure Under Chapter 9 Section 10 Securities Mark

    GLOBENEWSWIRE

    Orion Disclosure Under Securities Market Act (BlackRock)

    GLOBENEWSWIRE

    Orion Corporation: Manager™ transactions Niclas Lindstedt

    GLOBENEWSWIRE

    Orion Corporation: Managers transactions Outi Vaarala

    GLOBENEWSWIRE

    Orion Corporation: Managers’ transactions – Satu Ahomäki

    GLOBENEWSWIRE

    Orion Corporation: Managers’ transactions – Hao Pan

    GLOBENEWSWIRE

    Orion Group Financial Statement Release January–December 2024

    GLOBENEWSWIRE

    Notice to the Annual General Meeting of Orion Corporation

    GLOBENEWSWIRE

    Orion Approves Incentive Programs For Key Executives

    GLOBENEWSWIRE

    Orion Corp.: Disclosure Under Chapter 9 Section 10 Securities Mar

    GLOBENEWSWIRE

    Orion Corp: Disclosure Under Chapter 9 Section 10 Securities

    GLOBENEWSWIRE

    Orion Reports BlackRock Disclosure Under Securities Market Act

    GLOBENEWSWIRE

    Orion Discloses BlackRock Stake Under Securities Market Act

    PRESS RELEASE

    Disclosure Under Chapter 9 Section 10 of the Securities Market Act

    PRESS RELEASE

    Save the Date: Orion`s Capital Markets Day on 22 May 2025

    PRESS RELEASE

    Invenra, Orion Partner For Bispecific Antibody Cancer Therapy

    PRESS RELEASE

    Orion publishes Financial Statement Release for 2024

    PRESS RELEASE

    Orion Committee Prepares Proposals For Annual Meeting Agenda

    PRESS RELEASE

    Orion Announces Improved Financial Outlook For Coming Year

    PRESS RELEASE

    79,345 Orion Corporation A shares converted into B shares

    PRESS RELEASE

    Orion’s partner Bayer in China for 3rd indication of darolutamide

    PRESS RELEASE

    Orion and Marinus terminate agreement for ganaxolone in Europe

    PRESS RELEASE

    Orion and Marinus terminate agreement for ganaxolone in Europe

    #N/A

    Change in Orion Group Executive Management Board

    GLOBENEWSWIRE

    Orion Group Appoints Mikko as General Counsel Starting June 2025

    GLOBENEWSWIRE

    Abilita and Orion Announce Research Collab to Next-Gen Antibody

    PRESS RELEASE

    Orion Board Member Penalized for Delayed Transaction Notification

    GLOBENEWSWIRE

    Orion Corporation Enters Collaboration with Evariste on Inhibitors

    BUSINESSWIRE

    142,701 Orion Corporation A shares converted into B shares

    GLOBENEWSWIRE

    Orion Research Foundation grants EUR 1,109,000 for research in 2025

    GLOBENEWSWIRE

    Orion and Alligator Bio amend agreement 2 bispecific antibodies

    PRESS RELEASE

    Orion & Alligator Bioscience Amend Bispecific Antibodies Agreement

    #N/A

    Orion Corporation: Managers’ transactions – Henrik Stenqvist

    GLOBENEWSWIRE

    Orion Group Interim Report January–September 2024

    GLOBENEWSWIRE

    Orion Terminates ODM-111 Development Due To Narrow Window

    PRESS RELEASE

    Orion publishes Interim Report for Jan–Sept 2024

    GLOBENEWSWIRE

    Orion`s Partner Bayer Submits Application For Darolutamide

    GLOBENEWSWIRE

    Science Based Targets Initiative approves Orion’s Climate Targets

    GLOBENEWSWIRE

    Orion`s Partner Bayer Submits Application For Darolutamide

    GLOBENEWSWIRE

    Orion And Aitia Enter AI Drug Discovery Collaboration

    PR NEWSWIRE

    213,285 Orion Corporation A shares converted into B shares

    GLOBENEWSWIRE

    Darolutamide Plus ADT Reduces Prostate Cancer Progression

    GLOBENEWSWIRE

    Inside information: Orion upgrades full-year outlook for 2024

    GLOBENEWSWIRE

    Orion Corporation: Managers’ transactions – Satu Ahomäki

    GLOBENEWSWIRE

    Orion Corporation: Managers’ transactions – Niclas Lindstedt

    GLOBENEWSWIRE

    Orion Corporation: Managers’ transactions – Liisa Hurme

    GLOBENEWSWIRE

    Orion Corporation: Managers’ transactions – Hao Pan

    GLOBENEWSWIRE

    44,767 Orion Corporation A shares converted into B shares

    GLOBENEWSWIRE

    Orion Corporation: Managers’ transactions – Satu Ahomäki

    GLOBENEWSWIRE

    Orion Corporation’s financial reporting and Annual General Meeting in 2025

    GLOBENEWSWIRE

    Orion Group Half-Year Financial Report January–June 2024

    GLOBENEWSWIRE

    Orion publishes Half-Year Financial Report for January–June 2024

    PRESS RELEASE

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.